Statera Biopharma, Inc.: Nasdaq/NYSE listing notice — Statera Biopharma delisted from Nasdaq; trades OTC Pink under STAB

Statera Biopharma, Inc.

Received Nasdaq delisting notice Jan 10, 2023; trading suspended Jan 12, 2023.
Company intends to appeal to Nasdaq Listing and Hearing Review Council.
Stock now quoted on OTC Pink (STAB); applied for OTCQB listing with no assurance.
Nasdaq had granted continued listing subject to $1 bid and $2.5M equity by Jan 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Statera Biopharma, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(1), 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(1), 5550(b)(2)

Exact text from the filing

January 10, 2023, the Company received notice from Nasdaq that the Company’s was being delisted and that suspension of trading in the Company’s common stock will be effective at the open of business on January 12, 2023. The Company intends to appeal the delisting and request a review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council. Effective January 12, 2023, the Company’s common stock is quoted on OTC Pink Open Market under the symbol “STAB”. In addition, the Company has submitted an application for trading of its common stock on the OTCQB Venture Market (the “OTCQB”

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-001440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.